Objective: to evaluate the potential clinicopathological involvement
of macrophage migration inhibitory factor (MIF) in systemic lupus
erythematosus (SLE), and its relationship with lupus nephritis (LN)
through measuring serum and urinary MIF levels. Methods: A crosssectional case-control study was carried out on 30 SLE female
patients and 30 healthy age-matched females as a control group. SLE
activity was assessed by the Systemic Lupus Erythematosus Disease
Activity Index-2000 (SLEDAI-2k) and renal activity was evaluated
with the renal-SLEDAI (rSLEDAI-2k). SLE damage was evaluated
by the Systemic Lupus International Collaborating Clinics/American
College of Rheumatology (SLICC/ACR) damage index. Serum MIF
(sMIF), urinary MIF (uMIF) levels were assayed and
uMIF/creatinine ratio was estimated in all studied subjects. Results:
SLE patients had significantly higher levels of sMIF, uMIF and
uMIF/ creatinine ratio than the control group (p |
